Anil Bhattarai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anil Bhattarai has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Prabhat Khakural
Department of Cardiothoracic and Vascular Surgery, Manmohan Cardiothoracic Vascular and Transplant Center, Maharajgunj
3 shared publications - Bhagawan Koirala
Kathmandu Institute of Child Health, Budhanilkantha, Kathmandu, Nepal
2 shared publications - Ravi Kumar Baral
Department of Cardiothoracic and Vascular Surgery, Institute of Medicine, Kathmandu, Nepal
2 shared publications - Abhinav Bhattarai
Institute of Medicine Tribhuvan University Kathmandu Nepal
1 shared publication - Bijoy G. Rajbanshi
Nepal Mediciti Hospital
1 shared publication - Birendra Kunwar
Tribhuvan University
1 shared publication
Latest Publications
- Open Access
- 21 July 2026
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
Surgical Management of Acute Type A Aortic Dissection in Nepal: Challenges, Pitfalls and Early Outcomes
Background: Acute type A aortic dissection (ATAAD) is a surgical emergency associated with catastrophic consequences if untreated. We retrospectively reviewed patients who underwent surgical repair of ATAAD at the three primary referral centres in Nepal between 2006 and 2024. Methods: Of the 196 operated patients, complete data were available for 85. The mean age was 49.04 ± 13.95 years and 57 (67.1%) were men. Hypertension was present in 45 (52.9%) patients, 32 (37.7%) had a history of smoking and 6 (6.9%) presented with organ malperfusion. Results: Modified Bentall procedure with or without hemiarch replacement was performed in 62 (71.3%) patients due to aortic root involvement and significant aortic regurgitation. Deep hypothermic circulatory arrest with open distal anastomosis was performed in 22 (25.9%) patients. Femoral arterial cannulation was performed in 58 (66.6%) patients and right axillary artery cannulation in 21 (24.1%). Early mortality was 18 (21.17%). Conclusion: ATAAD remains a major surgical challenge in Nepal, characterised by younger patient age, delayed presentation, limited access to timely surgery and substantial financial constraints.
- 21 July 2026
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
Open AccessSurgical Management of Acute Type A Aortic Dissection in Nepal: Challenges, Pitfalls and Early Outcomes
Background: Acute type A aortic dissection (ATAAD) is a surgical emergency associated with catastrophic consequences if untreated. We retrospectively reviewed patients who underwent surgical repair of ATAAD at the three primary referral centres in Nepal between 2006 and 2024. Methods: Of the 196 operated patients, complete data were available for 85. The mean age was 49.04 ± 13.95 years and 57 (67.1%) were men. Hypertension was present in 45 (52.9%) patients, 32 (37.7%) had a history of smoking and 6 (6.9%) presented with organ malperfusion. Results: Modified Bentall procedure with or without hemiarch replacement was performed in 62 (71.3%) patients due to aortic root involvement and significant aortic regurgitation. Deep hypothermic circulatory arrest with open distal anastomosis was performed in 22 (25.9%) patients. Femoral arterial cannulation was performed in 58 (66.6%) patients and right axillary artery cannulation in 21 (24.1%). Early mortality was 18 (21.17%). Conclusion: ATAAD remains a major surgical challenge in Nepal, characterised by younger patient age, delayed presentation, limited access to timely surgery and substantial financial constraints.
- Open Access
- 30 June 2025
- Published by Nepal Journals Online (JOL) in Journal of College of Medical Sciences-Nepal
- Vol. 21 (2) , 104-108
Platelet Count Dynamics after Cardiopulmonary Bypass in Patient Undergoing Single Valve Replacement Surgery
Background Cardiopulmonary Bypass is a standard procedure used during valve surgery to provide circulatory support and allow surgical intervention to replace a malfunctioning or diseased heart valve. Cardiac Surgery involving cardiopulmonary bypass may lead to alterations in platelet count, affecting hemostasis and patient outcome adversely. A study was conducted with the objective of investigating the effect of cardiopulmonary bypass on pre-operative and post-operative platelet count and the factors predicting the circulating platelet count after single valve replacement surgery with the use of cardiopulmonary bypass.MethodsAn analytical cross-sectional study was conducted Manmohan Cardiothoracic Vascular and Transplant Center, Kathmandu, Nepal from September 2023 to February 2024. All the patients undergoing single valve replacement for rheumatic heart disease were included in the study. The perioperative platelet counts were compared to study the alteration in platelet count dynamics. Data was analyzed using SPSS 16.ResultsA total of eighty patients were studied. The median platelet count decreased to 170933.75 cells/µL from the pre-operative median platelet count of 235856.25 cells/µL, within 24 hours of operation. Similarly, after 24 hours of operation, the median platelet counts further decreased to 159753.75 cells/µL (n =80). Incidence of thrombocytopenia (<150×104/µL) was observed in 37.5% of patients within 24 hours and 41.3% after 24 hours post-operation.Conclusions The significant decrease in platelet counts following single valve replacement surgery with cardiopulmonary bypass underscores the impact of cardiac surgery on platelet count dynamics. Pre-operative platelet count, age, and bypass time emerged as independent predictors of postoperative platelet count.
- 30 June 2025
- Published by Nepal Journals Online (JOL) in Journal of College of Medical Sciences-Nepal
- Vol. 21 (2) , 104-108
Open AccessPlatelet Count Dynamics after Cardiopulmonary Bypass in Patient Undergoing Single Valve Replacement Surgery
Background Cardiopulmonary Bypass is a standard procedure used during valve surgery to provide circulatory support and allow surgical intervention to replace a malfunctioning or diseased heart valve. Cardiac Surgery involving cardiopulmonary bypass may lead to alterations in platelet count, affecting hemostasis and patient outcome adversely. A study was conducted with the objective of investigating the effect of cardiopulmonary bypass on pre-operative and post-operative platelet count and the factors predicting the circulating platelet count after single valve replacement surgery with the use of cardiopulmonary bypass.MethodsAn analytical cross-sectional study was conducted Manmohan Cardiothoracic Vascular and Transplant Center, Kathmandu, Nepal from September 2023 to February 2024. All the patients undergoing single valve replacement for rheumatic heart disease were included in the study. The perioperative platelet counts were compared to study the alteration in platelet count dynamics. Data was analyzed using SPSS 16.ResultsA total of eighty patients were studied. The median platelet count decreased to 170933.75 cells/µL from the pre-operative median platelet count of 235856.25 cells/µL, within 24 hours of operation. Similarly, after 24 hours of operation, the median platelet counts further decreased to 159753.75 cells/µL (n =80). Incidence of thrombocytopenia (<150×104/µL) was observed in 37.5% of patients within 24 hours and 41.3% after 24 hours post-operation.Conclusions The significant decrease in platelet counts following single valve replacement surgery with cardiopulmonary bypass underscores the impact of cardiac surgery on platelet count dynamics. Pre-operative platelet count, age, and bypass time emerged as independent predictors of postoperative platelet count.
- Open Access
- 21 August 2022
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2022, 1-8
CT-IGFBP-4 as a Predictive Novel Biomarker of Ischemic Cardiovascular Events and Mortality: A Systematic Review
Background and objective. Numerous novel biomarkers have been proposed for the early diagnosis of cardiovascular diseases. Measurement of the carboxyl-terminal (CT) fragment of IGFBP-4, the CT-IGFBP-4, has shown promising efficacy in cardiac risk assessment in various studies. We performed a systematic review of studies that accessed the utility and predictability of CT-IGFBP-4 in different ischemic cardiovascular events. Methods. The electronic databases PubMed, medRxiv, ScienceDirect, and Google Scholar were searched for relevant literature from inception to the 10th of December, 2021. Thus, retrieved literature was screened by title and abstract, followed by full-text screening based on the eligibility criteria. The risk of bias was accessed using the quality in prognostic studies (QUIPSs) tool. The data on cardiovascular outcomes about CT-IGFBP-4 levels were studied and the results were synthesized. Results. Five studies with a total of 1,417 participants were included in our study. The studies reported a low risk of bias. The mean age of the participants was 66.14 and more than 65 were males. Elevated CT-IGFBP-4 levels were associated with poor cardiovascular outcomes and increased mortality in severely ill patients. In contrast, there were no significant findings in the case of stable patients. Sandwich ELISA using lithium-heparin plasma provided a better detection limit of 0.15ng/ml, low cross-reactivity (Conclusion. CT-IGFBP-4 is an efficient biomarker for the prediction of MACE and mortality in patients with severe ischemic cardiovascular events.
- 21 August 2022
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2022, 1-8
Open AccessCT-IGFBP-4 as a Predictive Novel Biomarker of Ischemic Cardiovascular Events and Mortality: A Systematic Review
Background and objective. Numerous novel biomarkers have been proposed for the early diagnosis of cardiovascular diseases. Measurement of the carboxyl-terminal (CT) fragment of IGFBP-4, the CT-IGFBP-4, has shown promising efficacy in cardiac risk assessment in various studies. We performed a systematic review of studies that accessed the utility and predictability of CT-IGFBP-4 in different ischemic cardiovascular events. Methods. The electronic databases PubMed, medRxiv, ScienceDirect, and Google Scholar were searched for relevant literature from inception to the 10th of December, 2021. Thus, retrieved literature was screened by title and abstract, followed by full-text screening based on the eligibility criteria. The risk of bias was accessed using the quality in prognostic studies (QUIPSs) tool. The data on cardiovascular outcomes about CT-IGFBP-4 levels were studied and the results were synthesized. Results. Five studies with a total of 1,417 participants were included in our study. The studies reported a low risk of bias. The mean age of the participants was 66.14 and more than 65 were males. Elevated CT-IGFBP-4 levels were associated with poor cardiovascular outcomes and increased mortality in severely ill patients. In contrast, there were no significant findings in the case of stable patients. Sandwich ELISA using lithium-heparin plasma provided a better detection limit of 0.15ng/ml, low cross-reactivity (Conclusion. CT-IGFBP-4 is an efficient biomarker for the prediction of MACE and mortality in patients with severe ischemic cardiovascular events.
- Open Access
- 1 July 2022
- Published by Nepal Journals Online (JOL) in Journal of Kathmandu Medical College
- p. 124-127
Amplatzer atrial septal defect occluder device embolisation to right pulmonary artery
Atrial septal defect is a common congenital acyanotic heart disease which is treated with either surgical closure or transcatheter closure. Although surgical closure is gold standard, transcatheter device closure is gaining popularity worldwide and in Nepal due to favourable outcome in selected patients. Device migration following transvenous closure of atrial septal defect is a common problem but its lodgment in right pulmonary artery is a rarely encountered and reported clinical scenario. Here, the authors report a case of 42-year-old female who had an embolisation of Amplatzer septal occluder to right pulmonary artery requiring urgent surgical intervention to retrieve the device.
- 1 July 2022
- Published by Nepal Journals Online (JOL) in Journal of Kathmandu Medical College
- p. 124-127
Open AccessAmplatzer atrial septal defect occluder device embolisation to right pulmonary artery
Atrial septal defect is a common congenital acyanotic heart disease which is treated with either surgical closure or transcatheter closure. Although surgical closure is gold standard, transcatheter device closure is gaining popularity worldwide and in Nepal due to favourable outcome in selected patients. Device migration following transvenous closure of atrial septal defect is a common problem but its lodgment in right pulmonary artery is a rarely encountered and reported clinical scenario. Here, the authors report a case of 42-year-old female who had an embolisation of Amplatzer septal occluder to right pulmonary artery requiring urgent surgical intervention to retrieve the device.
- 28 January 2021
- Published by SAGE Publications in Perfusion
- Vol. 36 (5) , 470-475
Del Nido Cardioplegia in Coronary Artery Bypass Grafting Surgery: A safe, efficacious and economic alternative to St. Thomas solution; an experience from a developing nation
Del Nido cardioplegia is a newer solution getting popular worldwide, whereas in Nepal, St. Thomas cardioplegia solution is conventionally used. There is no national recommendation on cardioplegia solutions supported by evidences from Nepalese studies. This study aimed to evaluate and compare the efficacy of these solutions in Nepalese patients undergoing coronary artery bypass grafting. Patients undergoing coronary revascularization, from May 2018 to December 2019, were randomized into St. Thomas and del Nido groups based on the cardioplegia administered, with 45 patients in each group. Preoperative, intraoperative, and postoperative parameters and cost of cardioplegia preparation in the two groups were compared. The cardiopulmonary bypass time (106.13 ± 24.65 minutes vs 107.62 ± 18.69 minutes, p = 0.02), aortic cross clamp time (66.22 ± 15.40 minutes vs 72.07 ± 12.23 minutes, p = 0.04), volume (1059.22 ± 100.30 ml vs 1526.67 ± 271.81 ml, p < 0.001) and number of cardioplegia doses (1.00 ± 0.00 vs 2.51 ± 0.66, p < 0.001) were significantly lower with del Nido cardioplegia. A lower CPK-MB at second post-operative (59.91 ± 31.62 vs 73.82 ± 37.25, p = 0.03) and a higher left ventricle ejection fraction at discharge (56.33 ± 8.94% vs 50.45 ± 8.55%, p < 0.001) was observed in del Nido group. There was one death in St. Thomas group. ICU and hospital stay were similar in both groups. St. Thomas solution was found to be costlier than del Nido solution (USD 5.40 ± 0.96 vs USD 3.50 ± 0.34, p < 0.001). The del Nido cardioplegia was found to be efficacious, safe and more economical alternative to St. Thomas solution.
- 28 January 2021
- Published by SAGE Publications in Perfusion
- Vol. 36 (5) , 470-475
Del Nido Cardioplegia in Coronary Artery Bypass Grafting Surgery: A safe, efficacious and economic alternative to St. Thomas solution; an experience from a developing nation
Del Nido cardioplegia is a newer solution getting popular worldwide, whereas in Nepal, St. Thomas cardioplegia solution is conventionally used. There is no national recommendation on cardioplegia solutions supported by evidences from Nepalese studies. This study aimed to evaluate and compare the efficacy of these solutions in Nepalese patients undergoing coronary artery bypass grafting. Patients undergoing coronary revascularization, from May 2018 to December 2019, were randomized into St. Thomas and del Nido groups based on the cardioplegia administered, with 45 patients in each group. Preoperative, intraoperative, and postoperative parameters and cost of cardioplegia preparation in the two groups were compared. The cardiopulmonary bypass time (106.13 ± 24.65 minutes vs 107.62 ± 18.69 minutes, p = 0.02), aortic cross clamp time (66.22 ± 15.40 minutes vs 72.07 ± 12.23 minutes, p = 0.04), volume (1059.22 ± 100.30 ml vs 1526.67 ± 271.81 ml, p < 0.001) and number of cardioplegia doses (1.00 ± 0.00 vs 2.51 ± 0.66, p < 0.001) were significantly lower with del Nido cardioplegia. A lower CPK-MB at second post-operative (59.91 ± 31.62 vs 73.82 ± 37.25, p = 0.03) and a higher left ventricle ejection fraction at discharge (56.33 ± 8.94% vs 50.45 ± 8.55%, p < 0.001) was observed in del Nido group. There was one death in St. Thomas group. ICU and hospital stay were similar in both groups. St. Thomas solution was found to be costlier than del Nido solution (USD 5.40 ± 0.96 vs USD 3.50 ± 0.34, p < 0.001). The del Nido cardioplegia was found to be efficacious, safe and more economical alternative to St. Thomas solution.